Authors: SPARREBOORN A DEJONGE MJA LOOS WJ VANBEURDEN V PUNT CJA PLANTING AST VANDERBURG MEL COLAJORI E VERWEIJ J

Citation: A. Sparreboorn et al., PHARMACOKINETICS AND ORAL BIOAVAILABILITY OF 9-AMINO-CAMPTOTHECIN PEG1000 CAPSULES, European journal of cancer, 33, 1997, pp. 1112-1112

Authors: BRUFMAN G COLAJORI E GHILEZAN N LASSUS M MARTONI A PEREVODCHIKOVA N TOSELLO C VIARO D ZIELINSKI C KRAINER M SALZER H SCHULLER J DITTRICH C SCHEITHAUER W ZAMAGNI C AMBROSINI G COLUCCI G GENTILINI P ZANIBONI A PACINI P BIANCO R MUSTACCHI G DAPRILE M DEMATTEIS A OLIVEIRA C JORDAAN J GUDGEON A VANZYL J RAKOWSKY E INBAR M RATH P COHEN Y SHANI A FRIED G HEGG R NETO AB BADER G BRAGA RF VITOC C PUERTO VML VALLE AE SALAZAR JD SANCHEZ JC VILLELA GM FOUNTZILAS G

Citation: G. Brufman et al., DOUBLING EPIRUBICIN DOSE INTENSITY (100 MG M(2) VERSUS 50 MG/M(2)) INTHE FEC REGIMEN SIGNIFICANTLY INCREASES RESPONSE RATES - AN INTERNATIONAL RANDOMIZED PHASE-III STUDY IN METASTATIC BREAST-CANCER/, Annals of oncology, 8(2), 1997, pp. 155-162

Authors: VILLARGRIMALT A ARANDA E MASSUTI B BELON J ANTON A JIMENO JM CANDEL T DEPAREDES LG COLAJORI E

Citation: A. Villargrimalt et al., PHASE-II STUDY WITH IODODOXORUBICIN IN MEASURABLE ADVANCED COLORECTALADENOCARCINOMA - EFFECTIVE RESCUE USING WEEKLY HIGH-DOSE 5-FLUOROURACIL (WFU), Tumori, 80(2), 1994, pp. 124-127

Authors: EBERHARDT W NIEDERLE N WILKE H WEIDMANN B HENSS H ENGELHARDT R ZEIDLER D COLAJORI E KERPELFRONIUS S SEEBER S

Citation: W. Eberhardt et al., PHASE-II STUDY OF 4'-IODO-4'-DEOXYDOXORUBICIN IN PATIENTS WITH ADVANCED, MEASURABLE NONSMALL CELL LUNG-CANCER, Onkologie, 16(6), 1993, pp. 446-448